Clinical trials
Limited Stage Small Cell Lung Cancer clinical trials
Below are recruiting limited stage small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 460 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06911606RecruitingPhase 2
Serplulimab with chemotherapy before surgery for limited-stage small cell lung cancer
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07224152RecruitingPhase 1/Phase 2
NBTXR3 plus radiation for inoperable lung cancer
This trial tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation. You'll get one injection of NBTXR3 into your lung tumor, followed by standard radiation. It is for people with early-stage non-small cell lung cancer who cannot have surgery.
Houston, TexasAges 18 years+ - NCT07226999RecruitingPhase 2/Phase 3
A new study for people with extensive-stage small cell lung cancer using a study drug plus chemo
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Fayetteville, ArkansasAges 18 years+ - NCT07227597RecruitingPhase 1/Phase 2
Study of two experimental drugs for advanced small cell lung cancer
This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, for people with advanced small cell lung cancer. The goal is to see if this combination can help control the cancer, either as a first treatment or after initial standard therapy.
Santa Rosa, CaliforniaAges 18 years+ - NCT07221474RecruitingPhase 2
Study of a personalized vaccine plus chemo for lung cancer
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
Tampa, FloridaAges 18 years+ - NCT07203053RecruitingPhase 2
Tarlatamab for advanced small cell lung cancer after first treatment
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
AngersAges 18 years+ - NCT07198217RecruitingPhase 2
Chemo, radiation, and immunotherapy for lung cancer
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Zibo, ShandongAges 18–75 - NCT07198841RecruitingPhase 2
Studying IBI351 plus Cetuximab beta for a type of lung cancer
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07202611RecruitingPhase 2
Immune Cell Therapy for Advanced Lung Cancer
This study tests a new kind of cancer treatment using your own immune cells (called DC and NK cells) to fight advanced non-small cell lung cancer. It's for people who have already tried other treatments but need more options.
Huwei, YUNLINAges 20 years+ - NCT07190248RecruitingPhase 3
Calderasib plus other treatments for advanced non-small cell lung cancer
This trial tests a new drug called calderasib (MK-1084) combined with other treatments for people with advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination works better than current options.
Birmingham, AlabamaAges 18 years+ - NCT07191717RecruitingPhase 2
Imlunestrant and abemaciclib for early ER+ breast cancer
This trial tests whether adding two targeted drugs, imlunestrant and abemaciclib, to your usual hormone therapy can lower the chance of your breast cancer coming back. It is for people with early-stage ER+ breast cancer who have no signs of cancer on scans but have tiny amounts of tumor DNA in their blood (called ctDNA).
Los Angeles, CaliforniaAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
Denver, ColoradoAges 18 years+ - NCT07182682RecruitingPhase 3
Sunvozertinib after surgery for early-stage NSCLC with certain EGFR mutations
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
BeijingAges 18 years+ - NCT06030258RecruitingPhase 1/Phase 2
Study of IN10018 plus standard chemo for extensive-stage small cell lung cancer
This trial tests a new drug called IN10018 combined with standard chemotherapy (carboplatin and etoposide) and an immunotherapy (anti-PD-1/L1) for people with extensive-stage small cell lung cancer (ES-SCLC) who have not yet been treated. The goal is to see if adding IN10018 helps shrink tumors or slow the cancer's growth.
JinanAges 18–75 - NCT07167459Enrolling by invitationPhase 2
Personalized radiation for early stage lung cancer
This trial tests a personalized radiation treatment called SBRT for early-stage non-small cell lung cancer that is located in the outer part of the lung and cannot be removed with surgery. The goal is to see if this approach works well for people who cannot have surgery or choose not to.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07158489RecruitingPhase 2
New drug combo for advanced lung cancer after immunotherapy
This trial combines gemcitabine with ivonescimab to try to overcome resistance to immunotherapy in advanced non-small cell lung cancer. It's for people whose cancer has worsened after prior immunotherapy.
BadenAges 18 years+ - NCT07161388Recruiting
Durvalumab after chemoradiation for limited-stage small cell lung cancer
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
BeijingAges 18 years+ - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07154706RecruitingPhase 3
Taletrectinib vs placebo after surgery for ROS1-positive lung cancer
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT07138755RecruitingPhase 2
PD-1, chemo, and adaptive radiation for stage 3 lung cancer
This study tests if adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy and specially planned radiation works better for stage 3 lung cancer that cannot be surgically removed. It may be an option if you have not had previous treatment for this cancer.
Changsha, HunanAges 18–75 - NCT07130916RecruitingPhase 1
Aumolertinib study for European patients with lung cancer
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
Banja LukaAges 18 years+ - NCT07132918RecruitingPhase 2
Heart-Sparing Radiation for Thoracic Cancers
This trial tests a new way to plan radiation for cancers in the chest area (like lung, esophageal, or thymus cancers) that aims to protect the heart from high doses of radiation. It is for people who need daily radiation for at least three weeks and who are expected to live more than a year.
Madison, WisconsinAges 18 years+ - NCT07122258Recruiting
Using the CAROL device to treat early stage lung cancer
This trial tests a new device called the CAROL that uses heat to destroy small lung tumors during surgery. It is for people with a specific type of early-stage lung cancer (stage 1, tumor 2 cm or smaller) that is located in the outer part of the lung and can be removed by surgery.
Melbourne, VictoriaAges 18 years+
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for limited stage small cell lung cancer?
- Yes. Clin2 currently lists 460 recruiting limited stage small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a limited stage small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a limited stage small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Small Cell Lung Cancer Extensive Stage
- Non-small Cell Lung Cancer Stage III
- Non Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.